Published in Infect Immun on May 21, 2012
Clostridium difficile 027/BI/NAP1 encodes a hypertoxic and antigenically variable form of TcdB. PLoS Pathog (2013) 1.08
A novel multivalent, single-domain antibody targeting TcdA and TcdB prevents fulminant Clostridium difficile infection in mice. J Infect Dis (2014) 1.02
The host immune response to Clostridium difficile infection. Ther Adv Infect Dis (2013) 0.96
Mechanisms of protection against Clostridium difficile infection by the monoclonal antitoxin antibodies actoxumab and bezlotoxumab. Infect Immun (2014) 0.94
Protective efficacy induced by recombinant Clostridium difficile toxin fragments. Infect Immun (2013) 0.94
Cytotoxicity of Clostridium difficile toxin B does not require cysteine protease-mediated autocleavage and release of the glucosyltransferase domain into the host cell cytosol. Pathog Dis (2013) 0.90
Antibodies for treatment of Clostridium difficile infection. Clin Vaccine Immunol (2014) 0.87
Critical roles of Clostridium difficile toxin B enzymatic activities in pathogenesis. Infect Immun (2014) 0.86
Clostridium difficile virulence factors: Insights into an anaerobic spore-forming pathogen. Gut Microbes (2014) 0.86
Vaccination against Clostridium difficile using toxin fragments: Observations and analysis in animal models. Gut Microbes (2014) 0.85
The potential for emerging therapeutic options for Clostridium difficile infection. Gut Microbes (2014) 0.84
Identification of toxemia in patients with Clostridium difficile infection. PLoS One (2015) 0.84
Identification, immunogenicity, and cross-reactivity of type IV pilin and pilin-like proteins from Clostridium difficile. Pathog Dis (2014) 0.83
Beneficial effect of oral tigecycline treatment on Clostridium difficile infection in gnotobiotic piglets. Antimicrob Agents Chemother (2014) 0.82
The P2Y6 receptor mediates Clostridium difficile toxin-induced CXCL8/IL-8 production and intestinal epithelial barrier dysfunction. PLoS One (2013) 0.82
Clinical update for the diagnosis and treatment of Clostridium difficile infection. World J Gastrointest Pharmacol Ther (2014) 0.81
The roles of host and pathogen factors and the innate immune response in the pathogenesis of Clostridium difficile infection. Mol Immunol (2014) 0.81
Glucosyltransferase activity of Clostridium difficile Toxin B is essential for disease pathogenesis. Gut Microbes (2015) 0.80
An optimized, synthetic DNA vaccine encoding the toxin A and toxin B receptor binding domains of Clostridium difficile induces protective antibody responses in vivo. Infect Immun (2014) 0.80
Masking autoprocessing of Clostridium difficile toxin A by the C-terminus combined repetitive oligo peptides. Biochem Biophys Res Commun (2015) 0.79
Caspase activation as a versatile assay platform for detection of cytotoxic bacterial toxins. J Clin Microbiol (2013) 0.78
Clostridium difficile Toxins A and B: Insights into Pathogenic Properties and Extraintestinal Effects. Toxins (Basel) (2016) 0.77
Hyperimmune bovine colostrum as a novel therapy to combat Clostridium difficile infection. J Infect Dis (2014) 0.77
The Role of Rho GTPases in Toxicity of Clostridium difficile Toxins. Toxins (Basel) (2015) 0.77
A chimeric protein comprising the glucosyltransferase and cysteine proteinase domains of toxin B and the receptor binding domain of toxin A induces protective immunity against Clostridium difficile infection in mice and hamsters. Hum Vaccin Immunother (2015) 0.77
Utility of Clostridium difficile toxin B for inducing anti-tumor immunity. PLoS One (2014) 0.76
Newly identified bacteriolytic enzymes that target a wide range of clinical isolates of Clostridium difficile. Biotechnol Bioeng (2016) 0.76
Recombinant antigens based on toxins A and B of Clostridium difficile that evoke a potent toxin-neutralising immune response. Vaccine (2013) 0.76
Development of a Novel Vaccine Containing Binary Toxin for the Prevention of Clostridium difficile Disease with Enhanced Efficacy against NAP1 Strains. PLoS One (2017) 0.75
Pilin Vaccination Stimulates Weak Antibody Responses and Provides No Protection in a C57Bl/6 Murine Model of Acute Clostridium difficile Infection. J Vaccines Vaccin (2016) 0.75
Recombinant lipoprotein-based vaccine candidates against C. difficile infections. J Biomed Sci (2015) 0.75
Immunization with Recombinant TcdB-Encapsulated Nanocomplex Induces Protection against Clostridium difficile Challenge in a Mouse Model. Front Microbiol (2017) 0.75
An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med (2005) 18.10
A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med (2005) 16.59
Clostridium difficile--more difficult than ever. N Engl J Med (2008) 12.12
Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med (2011) 10.29
A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis (2007) 8.65
Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat Rev Microbiol (2009) 7.89
Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med (2010) 7.37
Clinical practice. Antibiotic-associated diarrhea. N Engl J Med (2002) 7.13
Clostridium difficile toxins: mechanism of action and role in disease. Clin Microbiol Rev (2005) 5.69
Toxin B is essential for virulence of Clostridium difficile. Nature (2009) 5.49
Effects of Clostridium difficile toxins given intragastrically to animals. Infect Immun (1985) 5.44
The role of toxin A and toxin B in Clostridium difficile infection. Nature (2010) 5.32
Host and pathogen factors for Clostridium difficile infection and colonization. N Engl J Med (2011) 4.62
Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet (2001) 4.59
Comparative genome and phenotypic analysis of Clostridium difficile 027 strains provides insight into the evolution of a hypervirulent bacterium. Genome Biol (2009) 3.66
A mouse model of Clostridium difficile-associated disease. Gastroenterology (2008) 3.65
Fatal pseudomembranous colitis associated with a variant clostridium difficile strain not detected by toxin A immunoassay. Ann Intern Med (2001) 2.72
Effects of the two toxins of Clostridium difficile in antibiotic-associated cecitis in hamsters. Infect Immun (1982) 2.65
Structure and mode of action of clostridial glucosylating toxins: the ABCD model. Trends Microbiol (2008) 2.25
Production of antitoxins to two toxins of Clostridium difficile and immunological comparison of the toxins by cross-neutralization studies. Infect Immun (1982) 2.14
Immunization of adult hamsters against Clostridium difficile-associated ileocecitis and transfer of protection to infant hamsters. Infect Immun (1987) 2.06
Systemic dissemination of Clostridium difficile toxins A and B is associated with severe, fatal disease in animal models. J Infect Dis (2011) 1.98
Clostridium difficile colitis associated with chronic renal failure. Nephrol Dial Transplant (1998) 1.94
Expression of recombinant Clostridium difficile toxin A and B in Bacillus megaterium. BMC Microbiol (2008) 1.89
Cytokine response by human monocytes to Clostridium difficile toxin A and toxin B. Infect Immun (1991) 1.87
Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI). Vaccine (2009) 1.85
Pathogenesis of Clostridium difficile infection. J Antimicrob Chemother (1998) 1.72
Association between IgG2 and IgG3 subclass responses to toxin A and recurrent Clostridium difficile-associated disease. Clin Gastroenterol Hepatol (2007) 1.70
Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea. Gastroenterology (2005) 1.62
Active and passive immunization to protect against antibiotic associated caecitis in hamsters. Dev Biol Stand (1983) 1.45
Structural organization of the functional domains of Clostridium difficile toxins A and B. Proc Natl Acad Sci U S A (2010) 1.44
Update on Clostridium difficile associated disease. Curr Opin Gastroenterol (2007) 1.44
Active and passive immunization against Clostridium difficile diarrhea and colitis. Vaccine (2004) 1.44
Piglet models of acute or chronic Clostridium difficile illness. J Infect Dis (2010) 1.38
Mouse relapse model of Clostridium difficile infection. Infect Immun (2011) 1.36
Evaluation of formalin-inactivated Clostridium difficile vaccines administered by parenteral and mucosal routes of immunization in hamsters. Infect Immun (1995) 1.35
Protective immunity against Clostridium difficile toxin A induced by oral immunization with a live, attenuated Vibrio cholerae vector strain. Infect Immun (1997) 1.34
An ultrasensitive rapid immunocytotoxicity assay for detecting Clostridium difficile toxins. J Microbiol Methods (2009) 1.34
Clostridium difficile colitis causing toxic megacolon, severe sepsis and multiple organ dysfunction syndrome. Intensive Care Med (2003) 1.28
Variations in TcdB activity and the hypervirulence of emerging strains of Clostridium difficile. PLoS Pathog (2010) 1.26
Serum antitoxin antibodies mediate systemic and mucosal protection from Clostridium difficile disease in hamsters. Infect Immun (1999) 1.25
Immunization with Bacillus spores expressing toxin A peptide repeats protects against infection with Clostridium difficile strains producing toxins A and B. Infect Immun (2011) 1.24
Clostridium difficile glucosyltransferase toxin B-essential amino acids for substrate binding. J Biol Chem (2007) 1.23
Safety and immunogenicity of increasing doses of a Clostridium difficile toxoid vaccine administered to healthy adults. Infect Immun (2001) 1.23
Antibody-enhanced, Fc gamma receptor-mediated endocytosis of Clostridium difficile toxin A. Infect Immun (2009) 1.21
Immunogenicity of a Salmonella typhimurium aroA aroD vaccine expressing a nontoxic domain of Clostridium difficile toxin A. Infect Immun (1999) 1.20
Intravenous immunoglobulin for the treatment of severe Clostridium difficile colitis: an observational study and review of the literature. J Hosp Med (2010) 1.19
Clostridium difficile vaccine and serum immunoglobulin G antibody response to toxin A. Infect Immun (2003) 1.18
Listeria-infected myeloid dendritic cells produce IFN-beta, priming T cell activation. J Immunol (2005) 1.16
Recurrent Clostridium difficile infection: causality and therapeutic approaches. Int J Antimicrob Agents (2009) 1.14
Local and systemic neutralizing antibody responses induced by intranasal immunization with the nontoxic binding domain of toxin A from Clostridium difficile. Infect Immun (1999) 1.09
A DNA vaccine targeting the receptor-binding domain of Clostridium difficile toxin A. Vaccine (2009) 1.08
Transcutaneous immunization with Clostridium difficile toxoid A induces systemic and mucosal immune responses and toxin A-neutralizing antibodies in mice. Infect Immun (2007) 1.06
Phase I dose finding studies of an adjuvanted Clostridium difficile toxoid vaccine. Vaccine (2012) 1.06
Stressed apoptotic tumor cells express heat shock proteins and elicit tumor-specific immunity. Blood (2001) 1.06
A nonsense mutation abrogates production of a functional enterotoxin A in Clostridium difficile toxinotype VIII strains of serogroups F and X. FEMS Microbiol Lett (1999) 1.05
The C-terminal ligand-binding domain of Clostridium difficile toxin A (TcdA) abrogates TcdA-specific binding to cells and prevents mouse lethality. FEMS Microbiol Lett (1997) 1.05
Is cardiorespiratory failure induced by bacterial toxins the cause of sudden infant death syndrome? Studies with an animal model (the rabbit). Toxicon (1995) 0.91
Adenovirus-based vaccination against Clostridium difficile toxin A allows for rapid humoral immunity and complete protection from toxin A lethal challenge in mice. Vaccine (2011) 0.91
Vaccination with parenteral toxoid B protects hamsters against lethal challenge with toxin A-negative, toxin B-positive clostridium difficile but does not prevent colonization. J Infect Dis (2011) 0.87
Clostridium difficile toxin A carboxyl-terminus peptide lacking ADP-ribosyltransferase activity acts as a mucosal adjuvant. Infect Immun (2004) 0.85
Construction of a fusion protein carrying antigenic determinants of enteric clostridial toxins. FEMS Microbiol Lett (2003) 0.80
Comparative metagenomics of microbial communities. Science (2005) 25.88
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
A genome-wide map of conserved microRNA targets in C. elegans. Curr Biol (2006) 10.14
Sorting of small RNAs into Arabidopsis argonaute complexes is directed by the 5' terminal nucleotide. Cell (2008) 9.02
Complete genome sequence of the apicomplexan, Cryptosporidium parvum. Science (2004) 5.64
A complex system of small RNAs in the unicellular green alga Chlamydomonas reinhardtii. Genes Dev (2007) 4.95
The genome of Cryptosporidium hominis. Nature (2004) 3.93
The landscape of C. elegans 3'UTRs. Science (2010) 3.32
Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Proc Natl Acad Sci U S A (2009) 3.29
A transient placental source of serotonin for the fetal forebrain. Nature (2011) 2.71
Human and mouse granzyme A induce a proinflammatory cytokine response. Immunity (2008) 2.57
Genome sequencing and comparison of two nonhuman primate animal models, the cynomolgus and Chinese rhesus macaques. Nat Biotechnol (2011) 2.37
Use of qigong therapy in the detoxification of heroin addicts. Altern Ther Health Med (2002) 2.28
Motor neuron degeneration in amyotrophic lateral sclerosis mutant superoxide dismutase-1 transgenic mice: mechanisms of mitochondriopathy and cell death. J Comp Neurol (2007) 2.17
Perforin triggers a plasma membrane-repair response that facilitates CTL induction of apoptosis. Immunity (2005) 2.11
Internalization of NK cells into tumor cells requires ezrin and leads to programmed cell-in-cell death. Cell Res (2009) 2.07
Radioprotection by plant products: present status and future prospects. Phytother Res (2005) 1.98
Systemic dissemination of Clostridium difficile toxins A and B is associated with severe, fatal disease in animal models. J Infect Dis (2011) 1.98
Deep sequencing of the oral microbiome reveals signatures of periodontal disease. PLoS One (2012) 1.96
KDOQI US commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKD-Mineral and Bone Disorder (CKD-MBD). Am J Kidney Dis (2010) 1.93
Cryptosporidiosis and microsporidiosis in ugandan children with persistent diarrhea with and without concurrent infection with the human immunodeficiency virus. Am J Trop Med Hyg (2005) 1.90
Expression of recombinant Clostridium difficile toxin A and B in Bacillus megaterium. BMC Microbiol (2008) 1.89
Relatedness of Vibrio cholerae O1/O139 isolates from patients and their household contacts, determined by multilocus variable-number tandem-repeat analysis. J Bacteriol (2010) 1.85
Self-regulation of Candida albicans population size during GI colonization. PLoS Pathog (2007) 1.85
Clostridium difficile toxin-induced inflammation and intestinal injury are mediated by the inflammasome. Gastroenterology (2010) 1.83
Human neural stem cells induce functional myelination in mice with severe dysmyelination. Sci Transl Med (2012) 1.82
Synthesis, characterization and development of a high-throughput methodology for the discovery of botulinum neurotoxin a inhibitors. J Comb Chem (2006) 1.79
Prevalence of Enterocytozoon bieneusi in swine: an 18-month survey at a slaughterhouse in Massachusetts. Appl Environ Microbiol (2002) 1.78
Structures of Clostridium botulinum Neurotoxin Serotype A Light Chain complexed with small-molecule inhibitors highlight active-site flexibility. Chem Biol (2007) 1.78
Glutamine deamidation and dysfunction of ubiquitin/NEDD8 induced by a bacterial effector family. Science (2010) 1.77
Enteric glia protect against Shigella flexneri invasion in intestinal epithelial cells: a role for S-nitrosoglutathione. Gut (2010) 1.73
Genomic survey of the non-cultivatable opportunistic human pathogen, Enterocytozoon bieneusi. PLoS Pathog (2009) 1.73
SalK/SalR, a two-component signal transduction system, is essential for full virulence of highly invasive Streptococcus suis serotype 2. PLoS One (2008) 1.64
Transplanted adult neural progenitor cells survive, differentiate and reduce motor function impairment in a rodent model of Huntington's disease. Exp Neurol (2006) 1.64
Cryptosporidium parvum in children with diarrhea in Mulago Hospital, Kampala, Uganda. Am J Trop Med Hyg (2003) 1.64
Enteric glia promote intestinal mucosal healing via activation of focal adhesion kinase and release of proEGF. Am J Physiol Gastrointest Liver Physiol (2011) 1.64
Developmentally regulated IkappaB expression in intestinal epithelium and susceptibility to flagellin-induced inflammation. Proc Natl Acad Sci U S A (2004) 1.64
Identification of hepoxilin A3 in inflammatory events: a required role in neutrophil migration across intestinal epithelia. Proc Natl Acad Sci U S A (2004) 1.63
The efficacy of pregabalin for prevention of catheter-related bladder discomfort: a prospective, randomized, placebo-controlled double-blind study. J Anesth (2014) 1.56
Respiratory cryptosporidiosis in HIV-seronegative children in Uganda: potential for respiratory transmission. Clin Infect Dis (2010) 1.56
GLI1 is a direct transcriptional target of EWS-FLI1 oncoprotein. J Biol Chem (2009) 1.56
Monoamine oxidase inactivation: from pathophysiology to therapeutics. Adv Drug Deliv Rev (2008) 1.56
Cancer chemoprevention by resveratrol: in vitro and in vivo studies and the underlying mechanisms (review). Int J Oncol (2003) 1.53
p38 Mitogen-activated protein kinase (MAPK) is a key mediator in glucocorticoid-induced apoptosis of lymphoid cells: correlation between p38 MAPK activation and site-specific phosphorylation of the human glucocorticoid receptor at serine 211. Mol Endocrinol (2005) 1.52
Enterocytozoon bieneusi among children with diarrhea attending Mulago Hospital in Uganda. Am J Trop Med Hyg (2002) 1.50
Human Stx2-specific monoclonal antibodies prevent systemic complications of Escherichia coli O157:H7 infection. Infect Immun (2002) 1.49
Human cord blood stem cells enhance neonatal right ventricular function in an ovine model of right ventricular training. Ann Thorac Surg (2010) 1.48
S-1-based therapy versus S-1 monotherapy in advanced gastric cancer: a meta-analysis. Tumour Biol (2014) 1.48
A Legionella type IV effector activates the NF-kappaB pathway by phosphorylating the IkappaB family of inhibitors. Proc Natl Acad Sci U S A (2009) 1.48
Monoamine oxidase A and repressor R1 are involved in apoptotic signaling pathway. Proc Natl Acad Sci U S A (2006) 1.46
Cryptosporidiosis in children in Sub-Saharan Africa: a lingering challenge. Clin Infect Dis (2008) 1.46
Differentiation of idiopathic spinal cord herniation from CSF-isointense intraspinal extramedullary lesions displacing the cord. Radiographics (2014) 1.45
Association of XRCC3 Thr241Met polymorphism and leukemia risk: evidence from a meta-analysis. Leuk Lymphoma (2014) 1.45
Notch-1 inhibition by Withaferin-A: a therapeutic target against colon carcinogenesis. Mol Cancer Ther (2010) 1.45
Right ventricular outflow pacing induces less regional wall motion abnormalities in the left ventricle compared with apical pacing. Europace (2011) 1.42
Need for supplementary data in a recent meta-analysis about risk of venous thromboembolism in patients with rheumatoid arthritis. Clin Rheumatol (2014) 1.39
Novel microRNAs uncovered by deep sequencing of small RNA transcriptomes in bread wheat (Triticum aestivum L.) and Brachypodium distachyon (L.) Beauv. Funct Integr Genomics (2009) 1.39
SMAD2, SMAD3 and SMAD4 mutations in colorectal cancer. Cancer Res (2012) 1.39
Piglet models of acute or chronic Clostridium difficile illness. J Infect Dis (2010) 1.38
Human antibody against shiga toxin 2 administered to piglets after the onset of diarrhea due to Escherichia coli O157:H7 prevents fatal systemic complications. Infect Immun (2005) 1.38
Mouse relapse model of Clostridium difficile infection. Infect Immun (2011) 1.36
Cryptosporidium hominis: experimental challenge of healthy adults. Am J Trop Med Hyg (2006) 1.35
An ultrasensitive rapid immunocytotoxicity assay for detecting Clostridium difficile toxins. J Microbiol Methods (2009) 1.34
Chemical probing reveals insights into the signaling mechanism of inflammasome activation. Cell Res (2010) 1.34
Monoamine oxidase A-mediated enhanced catabolism of norepinephrine contributes to adverse remodeling and pump failure in hearts with pressure overload. Circ Res (2009) 1.32
TGF-beta mediates PTEN suppression and cell motility through calcium-dependent PKC-alpha activation in pancreatic cancer cells. Am J Physiol Gastrointest Liver Physiol (2008) 1.31
Quantitative PCR for detection of Shigella improves ascertainment of Shigella burden in children with moderate-to-severe diarrhea in low-income countries. J Clin Microbiol (2013) 1.30
The reduced genome of the parasitic microsporidian Enterocytozoon bieneusi lacks genes for core carbon metabolism. Genome Biol Evol (2010) 1.30
Adult motor neuron apoptosis is mediated by nitric oxide and Fas death receptor linked by DNA damage and p53 activation. J Neurosci (2005) 1.26
Modulation of human intestinal epithelial cell IL-8 secretion by human milk factors. Pediatr Res (2003) 1.26
Non-equilibrium allele frequency spectra via spectral methods. Theor Popul Biol (2011) 1.26
Interactions of chronic lead exposure and intermittent stress: consequences for brain catecholamine systems and associated behaviors and HPA axis function. Toxicol Sci (2005) 1.25
The shikimate pathway and its branches in apicomplexan parasites. J Infect Dis (2002) 1.25
Antibody against TcdB, but not TcdA, prevents development of gastrointestinal and systemic Clostridium difficile disease. J Infect Dis (2012) 1.25
Molecular epidemiology of geographically dispersed Vibrio cholerae, Kenya, January 2009-May 2010. Emerg Infect Dis (2012) 1.24
A novel strategy for development of recombinant antitoxin therapeutics tested in a mouse botulism model. PLoS One (2012) 1.24
Identification of an endogenous inhibitor of the cardiac Na+/Ca2+ exchanger, phospholemman. J Biol Chem (2005) 1.23
Production and characterization of protective human antibodies against Shiga toxin 1. Infect Immun (2002) 1.23
Rapid CT diagnosis of acute appendicitis with IV contrast material. Emerg Radiol (2005) 1.22
Infectivity of a Cryptosporidium parvum isolate of cervine origin for healthy adults and interferon-gamma knockout mice. J Infect Dis (2002) 1.22
Antibody-enhanced, Fc gamma receptor-mediated endocytosis of Clostridium difficile toxin A. Infect Immun (2009) 1.21